RGT 9.33% 41.0¢ argent biopharma limited

Ann: September Quarterly Activity and Cashflow Report, page-61

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,311 Posts.
    lightbulb Created with Sketch. 283
    Is anyone here worried that the company has only 1-2 quarters of cash left in the bank at current average spend rates? Could another capital raise or further dilution in the very near future be on the cards?

    It's great to see revenues increase, but when these are loss-making revenues (as is currently the case), and with limited cash on hand, it could spell disaster.

    Looking at the last quarterly, the $413k in revenue cost the company $3.33M (if we exclude R&D, it still cost the company $2.2M). Even worse, the cost of sales alone exceeded the total revenues which demonstrates toxic Gross Margins ($916k COGS vs $413k Revenue) [September Quarterly Report - 31/10/19, pg. 7]
 
watchlist Created with Sketch. Add RGT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.